We create innovative treatments for nervous system damage due to injury or disease.
NervGen (TSX-V: NGEN, OTCQX: NGENF) is a clinical stage biotech company creating innovative treatments that enable the nervous system to repair itself following damage. NervGen’s lead drug candidate, NVG-291 is currently in a Phase 1 clinical trial. The company’s initial target indications are Alzheimer’s disease, spinal cord injury and multiple sclerosis.
Subscribe to our mailing list to stay up to date
In this inspiring and heartfelt video, Dr. Jerry Silver, Professor of Neurosciences, Case Western Reserve University, shares his journey and how the research carried out in his lab led to the formation of NervGen.
The video highlights how NervGen is developing Dr. Silver’s foundational discoveries into a disruptive technology that is aimed at changing the paradigm of how nervous system damage will be treated.
August 10, 2022
NervGen reported its financial results for the second quarter ended June 30, 2022 and provided an operational update.
May 31, 2022
Health Europa features NervGen Pharma and the potential of NVG-291 to treat Alzheimer’s.
February 11, 2022
Interview with Paul Brennan, NervGen President & CEO (Interview at 29:22 in video)